Renalytix plc

Company Profile

Company website
Sector
Medical Equipment and Services (Medical Equipment)
Description

Renalytix (NASDAQ: RNLX) (LSE: RENX) is the global founder and leader in the new field of bioprognosisTM for kidney health. The company has engineered a new solution that successfully enables early-stage chronic kidney disease progression risk assessment. The Company's lead product, KidneyIntelX, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com.

Investor Access

21 Oct
Event information
Click here to listen to Renalytix plc’s latest Earnings Call where management covered the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes.
Venue
Online
Time
Thursday 21 October 2021; 1:30pm BST
Financial Calendar
 Event  Date
Year End 30 June
Half  Year End 31 December
Preliminary Results* October
Interim Results* March
AGM* December

* Months based on previous announcements of this kind